What is the appropriate management plan for an 84-year-old patient with myelodysplastic syndrome (MDS)?

Management of MDS in an 84-Year-Old Patient

For an 84-year-old patient with MDS, management should be based on risk stratification using IPSS-R (or IPSS-M if available), with lower-risk disease managed primarily with supportive care and targeted therapies for cytopenias, while higher-risk disease requires hypomethylating agents (azacitidine) if the patient lacks major comorbidities, with allogeneic transplant generally not pursued at this age 1, 2.

Risk Stratification First

The critical first step is determining disease risk using IPSS-R scoring (incorporating cytopenias, bone marrow blast percentage, and cytogenetics) 2, 3. The molecular IPSS-M adds further prognostic refinement when genetic mutation data is available 4, 3. This risk classification fundamentally determines the treatment pathway.

Lower-Risk MDS Management

For lower-risk disease (IPSS-R low/intermediate risk), the approach focuses on managing cytopenias and maintaining quality of life:

For Anemia (Most Common):

• Erythropoiesis-stimulating agents (ESAs) like erythropoietin alfa are first-line for anemia in patients without del(5q), achieving responses in 15-40% of patients 2, 5
• Lenalidomide is most effective for transfusion-dependent anemia with del(5q) cytogenetics 2
• Luspatercept is recommended after ESA failure, particularly in MDS with ring sideroblasts (MDS-RS) 2, 3
• Imetelstat was approved in 2024 for transfusion-dependent lower-risk MDS 3

For Thrombocytopenia:

• Thrombopoietin receptor agonists (romiplostim, eltrombopag) have efficacy but should only be used when marrow blasts are <5% 2

Iron Overload Management:

• Iron chelation with deferasirox is strongly recommended if the patient has received 20-60 RBC transfusions or ferritin >1000-2500 U/L, particularly with evidence of cardiac iron overload (T2* <20 milliseconds on MRI) 2

Higher-Risk MDS Management

For higher-risk disease (IPSS-R high/very high risk), the approach shifts to disease modification:

Primary Treatment:

• Azacitidine 75 mg/m²/day subcutaneously for 7 consecutive days every 28 days is the standard first-line therapy for patients without major comorbidities 2, 5. At least 6 cycles should be administered before assessing response, as many patients only respond after several courses 2
• Alternative regimens like "5-2-2" schedules are acceptable for practical reasons 2
• Oral decitabine/cedazuridine is an alternative hypomethylating agent option 3, 5

Transplant Consideration:

At age 84, allogeneic stem cell transplantation is generally not recommended 2. The ESMO guidelines specify transplant for patients ≤70 years old without major comorbidities 2. While the NCCN guidelines don't specify an absolute age cutoff, the practical reality is that transplant-related mortality and comorbidities make this option unsuitable for most octogenarians 1.

Critical Age-Related Considerations

Frailty Assessment:

Chronological age alone is insufficient for treatment decisions 6. A comprehensive geriatric assessment should be performed:

• Timed Up and Go Test (TUGT) as initial screening for frailty 6
• Comprehensive geriatric assessment (CGA) to distinguish fit, pre-frail, and frail patients 6
• Fit patients receive standard-dose treatment; pre-frail patients receive individualized therapy; frail patients receive symptom-focused supportive care 6

Comorbidity Impact:

Comorbidities are essential predictors of survival and therapy tolerance 7. Renal function is particularly important as deferasirox cannot be used in renal failure 2.

Supportive Care (Universal)

Regardless of risk category, all patients require:

• RBC transfusions to maintain hemoglobin and quality of life 2
• Platelet transfusions for severe thrombocytopenia or bleeding 2
• Antibiotics for neutropenic infections 2
• Psychosocial support and connection with patient support groups 2

Treatment Failure Scenarios

• For hypomethylating agents: failure is defined as no response within 6 cycles of azacitidine or 4 cycles of decitabine 1
• No approved therapies exist for HMA-refractory disease; clinical trials should be strongly considered 1, 3
• Intensive AML-like chemotherapy is generally not appropriate at age 84 unless the patient is exceptionally fit with favorable cytogenetics and >10% marrow blasts as a bridge to transplant (which itself is unlikely at this age) 2

Key Pitfalls to Avoid

• Don't delay treatment waiting for "perfect" risk stratification - basic IPSS-R can guide initial management while awaiting molecular results
• Don't stop azacitidine prematurely - responses often require 4-6 cycles 2
• Don't overlook iron overload in transfusion-dependent patients, as cardiac complications significantly impact survival 2
• Don't assume age 84 automatically means "supportive care only" - fit patients with higher-risk disease benefit from hypomethylating agents 2, 4